Skip to Content

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

Sudipto Mukherjee from Cleveland Clinic in Ohio presents in this MEDtalk the results of a retrospective, observational cohort study of adults diagnosed with lower-risk myelodysplastic syndromes and treated with luspatercept.

Sudipto Mukherjee

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top